EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Monte Rosa Therapeutics Inc (GLUE) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Monte Rosa Therapeutics Inc $2.08, price $10.50, upside -80.2%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US61225M1027

MR Monte Rosa Therapeutics Inc logo Thin data Sep 24, 2026

Monte Rosa Therapeutics Inc

GLUE · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $2.08 · Strongly overvalued (−80.2%)
!Quality 45/100
!Mixed Growth (revenue YoY +63.5 %/yr)
!Loss-making · -31.2% net margin (FY2025)
!negative free cash flow
!Trails peers (1/8)
!Narrow moat 8/100
!Insider activity 46/100
!Evidence only low, so the estimate is less certain
Watch Monte Rosa Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$42.21 $2.50 Fair Value $2.08 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $2.50 – $42.21 · fair‑value band $1.37 – $2.60 · the $10.50 price screens above the $2.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Monte Rosa Therapeutics in your weekly email

Every Wednesday you see whether Monte Rosa Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.

Show more

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Stock analysis

Monte Rosa Therapeutics Inc (GLUE) currently trades at $10.50, while our model-based Fair Value estimate is $2.08, 80.2% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $1.37 (bear) to $2.60 (bull), the price of $10.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Monte Rosa Therapeutics Inc reported revenue of $124M in FY2025 versus $0 in FY2021. Reported net income was −$38.6M in FY2025.

Key figures

Market cap $1.1B · P/S ratio 38.6 · EPS (TTM) $−1.63 · Net margin −31.2% · Return on equity −42.7% · Return on assets (EBIT) −26.1% · Operating margin −548% · Revenue growth (YoY) −61.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, GLUE screens richer than that median.

Fair Value models

Bear $1.37 Fair Value $2.08 Bull $2.60
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.37 $1.83 $2.73 51
All 1 models by family
Asset-Based
NCAV (Graham) $1.37 $1.83 $2.73 51

Open the full fair value analysis →

Notify me when GLUE reaches fair value

Put GLUE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 45/100

Of which business quality 46 · Market factors (momentum, volatility) 31

Profitability 12
Margins and returns on capital today
Quality Growth 98
Are margins and returns improving?
Cashflow 2
Earnings quality: real cash, not paper profit
Fin. Strength 85
Balance sheet, leverage, solvency risk
Investment 81
Disciplined investing over empire-building
Low Volatility 12
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 48
Distance to the 52-week high (market factor)
Net Issuance 27
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GLUE screens overvalued: fair value 80% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Monte Rosa Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −81.5% · Bottom 25%
Profitability
Return on assets −21.6% · Below median
Net margin (TTM) −31.2% · Below median
Growth and dividend
Revenue growth −61.3% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.76× · Priciest 25%
P/S (TTM) 38.58× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Monte Rosa Therapeutics Inc · Fair Value
$2.08 −80%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Monte Rosa Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/GLUE

Frequently asked questions

Is Monte Rosa Therapeutics Inc (GLUE) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $2.08 versus a price of $10.50, about −80% upside (overvalued).
What is the fair value of GLUE?
Our model-based fair value for Monte Rosa Therapeutics Inc is $2.08 (as of Sep 24, 2026), built from audited fundamentals. The current price: $10.50.
What is the quality score of GLUE?
Monte Rosa Therapeutics Inc has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Monte Rosa Therapeutics Inc (GLUE)?
Our model-based price target is the fair value of $2.08 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $1.37, optimistic scenario $2.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Monte Rosa Therapeutics Inc stock forecast for 2026?
Our models put fair value at $2.08, about −80% upside versus a price of $10.50 (overvalued). Cautious scenario $1.37, optimistic scenario $2.60. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Monte Rosa Therapeutics Inc (GLUE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Monte Rosa Therapeutics Inc it is $2.08 per share (as of Sep 24, 2026), against a price of $10.50. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Monte Rosa Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, GLUE trades above its calculated fair value: price $10.50, fair value $2.08, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GLUE?
No. The price is what the market pays today ($10.50); the fair value is what the company's own numbers justify ($2.08). For Monte Rosa Therapeutics Inc the two are $8.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Monte Rosa Therapeutics Inc worth?
The market values Monte Rosa Therapeutics Inc at about $1.1B (market capitalisation, as of Sep 24, 2026). Per share that is $10.50; our models calculate a fair value of $2.08 per share.
What do the bullish and bearish scenarios say about GLUE?
Our models span a range for Monte Rosa Therapeutics Inc: cautious scenario $1.37, base $2.08, optimistic $2.60 per share (as of Sep 24, 2026, price $10.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Monte Rosa Therapeutics Inc (GLUE)?
Balance-sheet figures for Monte Rosa Therapeutics Inc (as of Sep 24, 2026): return on equity −42.7%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is GLUE from its 52-week high?
Monte Rosa Therapeutics Inc trades at $10.50, about 59% below its 52-week high of $25.31 and 42% above the low of $7.38 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $2.08 is for.
Which stocks are comparable to Monte Rosa Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Monte Rosa Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $10.50, calculated fair value $2.08 (−80%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GLUE calculated?
We run Monte Rosa Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Monte Rosa Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Monte Rosa Therapeutics Inc (GLUE)?
The closing price on Oct 2, 2026 was $10.50. Our model-based fair value is $2.08, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Monte Rosa Therapeutics Inc right now?
The price sits above even our optimistic bull case ($2.60). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($1.37 to $2.60) leaves room in how you read the outcome.

Key figures of Monte Rosa Therapeutics Inc

How large is the market capitalisation of Monte Rosa Therapeutics Inc (GLUE)?
The market capitalisation of Monte Rosa Therapeutics Inc is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Monte Rosa Therapeutics Inc (GLUE)?
The price-to-sales ratio of Monte Rosa Therapeutics Inc is 38.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Monte Rosa Therapeutics Inc (GLUE)?
Earnings per share at Monte Rosa Therapeutics Inc are $−1.63. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Monte Rosa Therapeutics Inc (GLUE)?
The net margin of Monte Rosa Therapeutics Inc is −31.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Monte Rosa Therapeutics Inc (GLUE)?
The return on equity (ROE) of Monte Rosa Therapeutics Inc is −42.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Monte Rosa Therapeutics Inc (GLUE)?
On an EBIT basis the return on assets of Monte Rosa Therapeutics Inc is −26.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Monte Rosa Therapeutics Inc (GLUE)?
The operating margin of Monte Rosa Therapeutics Inc is −548% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Monte Rosa Therapeutics Inc (GLUE)?
Revenue at Monte Rosa Therapeutics Inc is growing −61.3% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Monte Rosa Therapeutics Inc (GLUE) generate?
The free cash flow of Monte Rosa Therapeutics Inc is −$27.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Monte Rosa Therapeutics Inc (GLUE) hold?
Monte Rosa Therapeutics Inc holds more cash than debt, $90.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Monte Rosa Therapeutics Inc in the live analysis

One click puts Monte Rosa Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.